THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF UNITED KINGDOM DOMESTIC LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
26 September 2025
ANANDA PHARMA PLC
("Ananda" or the "Company")
Ananda terminates relationship with contractor for UCL/GOSH epilepsy trials and prioritises MRX1 for treatment of endometriosis and CIPN
Ananda Pharma plc (AQSE: ANA, OTC: ANANF), a UK-based biopharmaceutical company developing regulatory-approved cannabidiol medicines to treat complex, chronic conditions, announces that it has terminated its relationship with the contractor, which had been supplying MRX2 and MRX2T formulations for use in epilepsy studies at University College London (UCL) and Great Ormond St Hospital (GOSH).
While Ananda has yet to be notified by the contractor of the status of its contract with UCL/GOSH, the Company has received formal confirmation from UCL that it is no longer involved in the epilepsy studies. Ananda also understands that the contractor has been unable to fulfil its obligations under its agreement with UCL/GOSH and that UCL/GOSH is seeking an alternative supplier.
Given the ongoing delays to the epilepsy programme - with first patient dosing now not expected before 2027 and readouts unlikely until 2029 - and the intellectual property constraints in this indication, Ananda will now concentrate its resources on its lead programme: the patent-pending MRX1 formulation for the treatment of pain associated with endometriosis and chemotherapy-induced peripheral neuropathy (CIPN).
Melissa Sturgess, CEO of Ananda, commented:
"While it is disappointing that the epilepsy programme has stalled, this outcome allows us to focus our resources where the opportunity is strongest and the path to market is clearer. Ananda is determined to bring MRX1 CBD forward for the treatment of pain in endometriosis - a condition affecting 190 million women worldwide with few effective options - and in chemotherapy-induced peripheral neuropathy. These are areas of great unmet need where we believe MRX1 can make a real difference for patients. We wish UCL and GOSH well in their continued efforts in refractory epilepsies and remain available to support them in any way we can."
About Ananda Pharma
Ananda Pharma (AQSE: ANA OTCQB: ANANF) is a UK-based biopharmaceutical company developing regulatory approved , cannabidiol medicines to treat complex, chronic conditions, including endometriosis (funded by NHS Scotland) and chemotherapy induced peripheral neuropathy (funded by NIHR). The Company is led by successful entrepreneurs, ex-GW Pharmaceutical executives and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh.
For more information, please visit our website :
To stay up to date with Ananda's news please follow our social media channels:
· Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93
· Instagram: https://www.instagram.com/anandapharmaplc/
· LinkedIn : https://www.linkedin.com/company/anandapharma
· X : https://twitter.com/AnandaPlc
· Investor Meet Company: https://www.investormeetcompany.com/ananda-pharma-plc/register-investor
-Ends-
For the purposes of UK MAR, Melissa Sturgess, a Director and CEO of the Company arranged for the release of this information.
| ANANDA PHARMA PLC |
+44 (0)7463 686 497 |
| |
|
| Chief Executive Officer |
|
| Melissa Sturgess |
|
| |
|
| Finance Director |
|
| Jeremy Sturgess-Smith |
|
|
|
|
| SP ANGEL CORPORATE FINANCE LLP |
|
|
|
|
| Corporate Finance |
+44 (0)20 3470 0470 |
| Richard Morrison |
|
| Josh Ray |
|
| |
|
| Corporate Broking |
|
| Vadim Alexandre Abigail Wayne |
|
| Rob Rees
|
|
| |
|
| VIRIDIAN CAPITAL ADVISORS (US) Scott Greiper |
+1 (646) 330-0704
|
https://investors.anandapharma.co.uk/link/PREREr
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.